NYSE:PFEPharmaceuticals
How Investors May Respond To Pfizer (PFE) Prostate Cancer Combo Drug Label Expansion Push
Earlier this week, Pfizer announced that the FDA accepted for Priority Review a supplemental application for TALZENNA plus XTANDI in men with HRR gene‑altered metastatic castration‑sensitive prostate cancer, supported by Phase 3 TALAPRO‑3 data showing a reduced risk of radiographic progression or death versus XTANDI alone.
If approved, this would move the TALZENNA–XTANDI combination into an earlier stage of prostate cancer, potentially broadening its clinical role and reinforcing Pfizer’s...